3-(4-Hydroxy-butyl)-benzonitrile | 92367-54-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-Hydroxy-butyl)-benzonitrile
• 英文别名: 3-(4-Hydroxybutyl)benzonitrile
• CAS: 92367-54-9
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: ZZMCWOJNPOYJIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-Hydroxy-butyl)-benzonitrile 在 Lindlar's catalyst chromium(VI) oxide 、 硫酸 、 2,4,6-三异丙基苯磺酰叠氮化物 、 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 lithium hexamethyldisilazane 作用下， 以 乙醚 、 乙醇 、 丙酮 为溶剂， -78.0~25.0 ℃ 、310.27 kPa 条件下， 反应 1.53h， 生成 Methyl 4-(3-cyanophenyl)-2-[(4-phenylbenzoyl)amino]butanoate
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y
• 作为产物：
  描述：

  间溴苯甲腈 在 Lindlar's catalyst 哌啶 、 四(三苯基膦)钯 、 氢气 作用下， 以 乙醇 为溶剂， 80.0 ℃ 、310.27 kPa 条件下， 反应 5.0h， 生成 3-(4-Hydroxy-butyl)-benzonitrile
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y

文献信息

• [EN] PHENETHANOLAMINE DERIVATIVES<br/>[FR] DERIVES DE LA PHENETHANOLAMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2003091204A1

  公开（公告）日：2003-11-06

  The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式(I)的新化合物，或其盐、溶剂合物或生理功能衍生物，以及其制备方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸道疾病中的应用。
• Novel Propargyl-Linked Bisubstrate Analogues as Tight-Binding Inhibitors for Nicotinamide <i>N</i>-Methyltransferase
  作者：Dongxing Chen、Linjie Li、Krystal Diaz、Iredia D. Iyamu、Ravi Yadav、Nicholas Noinaj、Rong Huang

  DOI：10.1021/acs.jmedchem.9b01255

  日期：2019.12.12

  Nicotinamide N-methyltransferase (NNMT) catalyzes the methyl transfer from the cofactor S-adenosylmethionine to nicotinamide and other pyridine-containing compounds. NNMT is an important regulator for nicotinamide metabolism and methylation potential. Aberrant expression levels of NNMT have been implicated in cancer, metabolic, and neurodegenerative diseases, which makes NNMT a potential therapeutic

  烟酰胺N-甲基转移酶（NNMT）催化从辅因子S-腺苷甲硫氨酸到烟酰胺和其他含吡啶化合物的甲基转移。NNMT是烟酰胺代谢和甲基化潜力的重要调节剂。NNMT的异常表达水平与癌症，代谢和神经退行性疾病有关，这使NNMT成为潜在的治疗靶标。因此，有效的和选择性的NNMT抑制剂可作为研究NNMT在其介导疾病中的作用的有价值的工具。在这里，我们应用了一种合理的策略，通过新型的炔丙基接头设计并合成了紧密结合的双底物抑制剂LL320。LL320演示了K i值为1.6±0.3 nM，是迄今为止最有效的抑制剂。LL320的共晶结构证实了它与NNMT上底物和辅因子结合位点的相互作用。重要的是，这是使用炔丙基接头构建有效的甲基转移酶抑制剂的第一个例子，这将扩大我们对甲基转移过渡态的理解。
• Phenethanolamine derivatives
  申请人：Box Charles Philip

  公开号：US20050256201A1

  公开（公告）日：2005-11-17

  The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明与公式（I）的新化合物有关，或其盐，溶剂合物或生理功能衍生物，以及其制造过程，包含它们的制药组合物，并且它们在治疗中的使用，特别是在呼吸系统疾病的预防和治疗中的使用。
• PHENETHANOLAMINE DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1497261A1

  公开（公告）日：2005-01-19
• US7271197B2
  申请人：——

  公开号：US7271197B2

  公开（公告）日：2007-09-18